BioCentury
ARTICLE | Strategy

Value chain filling

September 13, 2004 7:00 AM UTC

MyoContract AG and Graffinity AG hope that by merging to create Santhera AG, with discovery capabilities and a late-stage clinical program, they will be able to attract significantly more investors and possibly be ready for an IPO in about 12 months.

The merged entity combines Graffinity's fragment-based discovery platform and preclinical pipeline in metabolic indications, with MyoContract's late-stage clinical program and preclinical pipeline in musculoskeletal therapies. ...